Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

compulsory licence

- PMLiVE

AstraZeneca bullish on diabetes franchise fortunes

Other big pharma firms face a difficult 2015, but AZ is confident it won't

- PMLiVE

NICE gives nod to blood cancer drug Gazyvaro

Roche’s leukaemia drug to be used in combination with chemotherapy

Eli Lilly HQ

German court overturns patent on Lilly blockbuster Alimta

Verdict means Actavis can launch generic after December

Bristol-Myers Squibb (BMS) building

Opdivo gains new US lung cancer licence

Adds to Bristol-Myers Squibb’s therapeutic vaccine’s melanoma indication

EU flag

New cancer meds and drug extensions top CHMP recommendations

Drugs for rare disease, oncology and diabetes top regulator’s endorsements

- PMLiVE

Novartis and GSK complete oncology and vaccines swap

Follows Swiss company's decision to divest its BRAF and MEK inhibitors to Array BioPharma

National Institute for Health and Care Excellence NICE logo

NICE backs biosimilars in rheumatoid arthritis guidance

Seven biologic drugs (DMARDs) and two biosimilars recommended

France flag

French pharma growth restricted by generics

New analysis finds country’s market value will grow only modestly in the coming years

- PMLiVE

Roche’s Zelboraf combination to receive priority FDA review

US regulator to assess drug's use with cobimetinib for melanoma within six months

- PMLiVE

Merck takes promotional responsibility for Erbitux in Japan

Currently co-promotes the drug withBristol-Myers Squibb

- PMLiVE

Takeda’s lung cancer drug motesanib flunks another trial

Drug was unable to extend progression-free survival in study of 400 patients

Roche Basel Switzerland

Roche taps Qualcomm for remote health monitoring

Builds on collaboration with Novartis on remote trial observation

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links